| Title |
Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma
|
|---|---|
| Published in |
Core Evidence, April 2011
|
| DOI | 10.2147/ce.s13838 |
| Pubmed ID | |
| Authors |
Salvia Jain, Catherine Diefenbach, Jasmine Zain, Owen A O’Connor |
| Abstract |
Proteasome inhibition forms the cornerstone of antimyeloma therapy. The first-in-class proteasome inhibitor, bortezomib, either alone or in combination with other chemotherapeutic agents, induces high overall response rates and response qualities in patients with clinically and molecularly defined high-risk disease. However, resistance to bortezomib and neurotoxicity associated with the treatment remain challenging issues. Carfilzomib is a novel, well tolerated, irreversible proteasome inhibitor with minimal neurotoxicity. Carfilzomib demonstrates promising activity in myeloma patients who are refractory to bortezomib and immunomodulatory agents. This review focuses on the pharmacology, safety, and efficacy of carfilzomib for the treatment of multiple myeloma in bortezomib-naïve and bortezomib-exposed populations. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 42 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Australia | 1 | 2% |
| Unknown | 41 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 10 | 24% |
| Student > Ph. D. Student | 9 | 21% |
| Researcher | 7 | 17% |
| Other | 6 | 14% |
| Student > Master | 3 | 7% |
| Other | 5 | 12% |
| Unknown | 2 | 5% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 11 | 26% |
| Agricultural and Biological Sciences | 11 | 26% |
| Chemistry | 6 | 14% |
| Biochemistry, Genetics and Molecular Biology | 3 | 7% |
| Psychology | 3 | 7% |
| Other | 5 | 12% |
| Unknown | 3 | 7% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 April 2020.
All research outputs
#7,960,512
of 25,374,647 outputs
Outputs from Core Evidence
#32
of 77 outputs
Outputs of similar age
#41,919
of 120,716 outputs
Outputs of similar age from Core Evidence
#1
of 2 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one has received more attention than most of these and is in the 67th percentile.
So far Altmetric has tracked 77 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.2. This one has gotten more attention than average, scoring higher than 54% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 120,716 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 64% of its contemporaries.
We're also able to compare this research output to 2 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them